Table 1.
Hospitalized patients with COVID-19-infection und vaccination breakthrough (CW 28–36)
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | |
|---|---|---|---|---|---|---|---|---|---|
| Sex | Male | Male | Male | Male | Male | Female | Female | Male | Male |
| Age (yr) | 75 | 80 | 44 | 62 | 62 | 84 | 90 | 85 | 72 |
| Coexisting conditions | |||||||||
| - Heart failure | + | + | + | + | + | – | + | – | + |
| - Arrhythmia | + | + | – | + | + | – | + | + | + |
| - Hypertension | + | + | + | – | – | + | + | – | + |
| - Diabetes mellitus | + | – | – | + | + | – | + | – | – |
| - Renal insufficiency (chronic) | + | + (Dialysis) | – | – | – | – | + | – | + |
| - Sleep aponea | + | – | – | – | – | – | + | – | + |
| - Anaemia | – | + | – | + | + | – | + | + | – |
| - Malignancy (Prostate) | – | – | – | – | + | – | – | – | + |
| - Transplantation (Kidney) | – | – | + | + | – | – | – | – | – |
| - Stroke | + | – | – | – | – | – | – | – | – |
| - M. Parkinson | – | – | – | – | – | + | – | – | – |
| - Impaired immune status (drugs) | – | – | + | + | – | – | – | – | – |
| - Hyperlipidaemia | – | – | – | – | – | – | – | – | – |
| - Dementia | – | + | – | – | – | + | + | – | – |
| - Nicotine abuse | – | – | – | – | – | – | – | – | – |
| - Arterial occlusive disease | + | – | – | – | – | – | – | + | – |
| - BMI > 30 kg/m2 | – | – | – | – | – | + | – | + | |
| Vaccine |
BNT162b2 (Pfizer-BioNTech) |
BNT 162b2 (Pfizer-BioNTech) |
BNT162b2 (Pfizer-BioNTech) |
BNT162b2 (Pfizer-BioNTech) |
BNT162b2 (Pfizer-BioNTech) |
BNT162b2 (Pfizer-BioNTech) |
BNT162b2 (Pfizer-BioNTech) |
BNT162b2 (Pfizer-BioNTech) |
BNT162b2 (Pfizer-BioNTech) |
| Time from first to second vaccine dose [d] | 21 | 21 | 22 | 29 | 21 | 21 | 24 | 22 | 21 |
| Time from second vaccination to infection [d] | 60 | 99 | 70 | 104 | 38 | 211 | 134 | 131 | 63 |
| Use of medical masks before vaccination breakthrough | – | + | – | + | + | – | – | – | – |
| Immunization of close contacts before vaccination breakthrough |
+ Wife, Daughter-in-law |
+ Wife |
– Wife, daughter |
– Single |
– Wife, daughter |
+ Husband |
+ Daughter |
– Daughter |
+ Wife |
| Travel history before vaccination breakthrough | – | + | + | – | + | – | – | – | – |
| Onset of COVID-19-specific symptoms and consultation of a physician [d] | 1 | 1 | 11 | 9 | 7 | 1 | 1 | 5 | 4 |
| Symptoms of COVID-19- infection and vaccination breakthrough | Fever, dyspnoea | Cough, dyspnoea | Fever, cough, dyspnoea | Fever, cough, dyspnoea | Dyspnoea | Fever, cough | Fever, dyspnoea | Dyspnoea | Fever, dyspnoea, diarrhoea |
|
Reason for PCR testing -Clinical suspicion |
+ | + | + | + | + | + | + | + | + |
|
Intensive care (day of hospitalization) -Mechanical ventilation [d] |
+ (3) + / 7 |
+ (2) – |
+ (4) – |
– – |
+ (11) + / 2 |
– – |
– – |
– – |
+ (4) + / 3 |
| Ct valuesN1/N2 at the time of vaccination breakthrough | 20/23 | 14/15 | 17/19 | 17/20 | 33/35 | 13/15 | 16/18 | 16/18 | 19/20 |
|
Anti-SARS-CoV-2-S [U/ml] Anti-SARS-CoV-2-N [COI] |
Day 2; > 250 Positive |
Day 3; 250 Positive |
Day 3; 0,4 Negative |
Day 2; < 0,4 Negative |
Day 3; > 250 Positive |
Day 1; 42 Negative |
Day 2; 73 Negative |
Day 1; > 250 Negative |
Day 1; 93 Negative |
| VOC |
B.1.617.2 (Delta) |
B.1.617.2 (Delta) |
B. 1.617.2 (Delta) |
B. 1.617.2 (Delta) |
Not determined |
B. 1.617.2 (Delta) |
B. 1.617.2 (Delta) |
B. 1.617.2 (Delta) |
B. 1.617.2 (Delta) |
|
Outcome -Discharge [d] -Exitus letalis [d] |
– + (13) |
+ (38) – |
+ (19) – |
+ (22) – |
+ (30) – |
+ (5) – |
+ 12) – |
+ (8) – |
– + (7) |
CW calendar week, yr year, + yes, – no, BMI Body Mass Index, d day, Ct Cycle threshold, S spike, N nucleocapsid, COI cutoff index, VOC Variants of Concern